SynthesisCurrent oncology (Toronto, Ont.)2019

Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours.

Nathan D Gay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.